<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733733</url>
  </required_header>
  <id_info>
    <org_study_id>Euro-NHB</org_study_id>
    <nct_id>NCT00733733</nct_id>
  </id_info>
  <brief_title>Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor</brief_title>
  <acronym>ATG</acronym>
  <official_title>A Prospective, Randomized, Open, Multicenter Study to Evaluate the Efficacy and Tolerability of Induction Therapy With a Single High-Dose Anti-T-Lymphocyte Globulin (ATG) in Renal Transplant Patients With a Kidney From a Non-Heart-Beating Donor and Tacrolimus, Mycophenolate Mofetil, and Steroids as Basic Immunosuppression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the greatest problems in renal transplantation is the shortage of donor kidneys.
      Kidneys of non-heart-beating donors (NHB) are a possible solution, but transplantation is
      accompanied with a high percentage of acute renal failure, caused by ischemia-reperfusion
      injury. The increased ischemia-reperfusion injury results in an increased immune activation,
      which can lead to more injury of the kidney and additional acute rejections. The hypothesis
      of this trial is that ischemia-reperfusion injury can be diminished by ATG. ATG could have
      additional favourable effects. To investigate this half of the patients is treated with
      additional ATG to the standard immunosuppressive treatment. Calcineurin inhibitors are not
      diminished during the first days after transplantation to investigate whether ATG has special
      effects on ischemia-reperfusion injury.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of initial delayed graft function (defined as need for dialysis)</measure>
    <time_frame>Within three months after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of initial delayed graft failure</measure>
    <time_frame>Within 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary never-functioning grafts</measure>
    <time_frame>Within 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejections (biopsy proven)</measure>
    <time_frame>Within 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function as determined by MDRD</measure>
    <time_frame>At 1, 2, 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>At 1, 2, 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with arterial hypertension</measure>
    <time_frame>At 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with antihypertensive drugs (and the number of different classes of antihypertensive drugs)</measure>
    <time_frame>At 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of hyperlipidemic patients</measure>
    <time_frame>At 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of post transplant diabetes mellitus</measure>
    <time_frame>During 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cytomegalovirus infection</measure>
    <time_frame>During 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of tumours/PTLD</measure>
    <time_frame>At 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>At 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of other infections</measure>
    <time_frame>During 3 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microalbuminuria</measure>
    <time_frame>At 1, 2, 3 months after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Renal Transplant Patients</condition>
  <condition>Recipients of a Kidney From a Non-Heart-Beating Donor</condition>
  <arm_group>
    <arm_group_label>ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard immunosuppressive treatment for renal transplantation including tacrolimus/MMF/prednisolone without ATG treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG Fresenius</intervention_name>
    <description>One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)</description>
    <arm_group_label>ATG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-heart-beating-donors (Maastricht III/IV)

          -  Female patients of childbearing age agree to maintain effective birth control practice
             during the study.

        Exclusion Criteria:

          -  Pregnant or lactating women at the time of randomization.

          -  Patients and donors are ABO incompatible.

          -  Women having had &gt;3 pregnancies (including abortions if no consistent data on PRA or
             anti-donor antibodies are available).

          -  Patients with hypersensibility to rabbit proteins, previous treatment with rabbit IgG,
             or known intolerance to any component of basal immunosuppression.

          -  Patients with leukocytes &lt;3,000/mm3 and/or platelets &lt;50,000/mm3 before initiation of
             transplant.

          -  Patients, who are HIV positive.

          -  Patients subjected to previous transplants or candidates for multiple transplants
             (e.g. SKP).

          -  Patients, who are unlikely to comply with the visit schedule in the protocol and
             patients who cannot communicate reliably with the investigator.

          -  Patients with pulmonary oedema or with other signs of overhydration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>andries hoitsma, prof.dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St Radboud Hospital, Nijmegen, the Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andries Hoitsma, Prof. Dr.</last_name>
    <phone>+31243614761</phone>
    <email>a.hoitsma@nier.umcn.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luuk Hilbrands, Dr.</last_name>
    <phone>+31243614761</phone>
    <email>l.hilbrands@nier.umcn.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMC St Radboud Hospital</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>andries hoitsma, prof. dr.</last_name>
      <phone>+31243614761</phone>
      <email>a.hoitsma@nier.umcn.nl</email>
    </contact>
    <contact_backup>
      <last_name>Luuk Hilbrands, Dr.</last_name>
      <phone>+31243614761</phone>
      <email>l.hilbrands@nier.umcn.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Martijn hoogen vd, drs.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <last_update_submitted>August 12, 2008</last_update_submitted>
  <last_update_submitted_qc>August 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. A.J. Hoitsma</name_title>
    <organization>UMC St Radboud Hospital</organization>
  </responsible_party>
  <keyword>kidney</keyword>
  <keyword>transplantation</keyword>
  <keyword>non-heart-beating donor</keyword>
  <keyword>delayed graft function</keyword>
  <keyword>Antithymocyte globulin</keyword>
  <keyword>ischemia-reperfusion damage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

